Publications
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind,…
Final results from the Phase I study expansion cohort of the selective FGFR inhibitor Debio 1347 in patients with solid…
Debio 1143 Mode of Action: a Broad Chemo-Radio and Immuno-Therapy Sensitizer
Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study
DEBIO 1347 In Patients With GastroIntestinal Cancers Harboring An FGFR Gene Fusion: Preliminary Results
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid…
FUZE Clinical Trial: a Phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of the tumor histology
New sample preparation method enabling PCR-based pathogen identification directly from blood to accelerate blood stream infection (BSI) diagnosis